MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
512.65
-1.14
-0.22%
After Hours: 512.66 +0.01 +0.00% 16:30 06/26 EDT
OPEN
517.66
PREV CLOSE
513.79
HIGH
532.33
LOW
505.63
VOLUME
2.50M
TURNOVER
--
52 WEEK HIGH
615.00
52 WEEK LOW
276.67
MARKET CAP
11.82B
P/E (TTM)
-40.0937
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI), Madrigal Pharmaceuticals (MDGL) and Verastem (VSTM)
TipRanks · 3d ago
Is Madrigal Pharmaceuticals’ (MDGL) Expanded Shelf and Inducement Plan Reframing Its Equity Strategy Narrative?
Simply Wall St · 4d ago
Madrigal Pharmaceuticals grants 1,397 inducement RSUs to five new employees under 2025 plan
PUBT · 4d ago
MADRIGAL PHARMACEUTICALS ANNOUNCES GRANTS OF INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 4d ago
Weekly Report: what happened at MDGL last week (0615-0619)?
Weekly Report · 5d ago
Madrigal Shareholders Approve 2026 Equity Compensation Plans
TipRanks · 06/17 21:14
Madrigal Pharmaceuticals management to meet with Piper Sandler
TipRanks · 06/17 20:21
Madrigal Pharmaceuticals adopts nonqualified deferred compensation plan effective Aug. 1
PUBT · 06/17 20:07
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.